Atara Biotherapeutics
Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. Working at Atara People at Atara are high integrity, collaborative, roll-up-your-sleeves types who are deeply committed to putting patients first and advancing medical care with demonstrated urgency. With many accomplished people at Atara, we share humility, flexibility, respect, teamwork, good judgment and being practical in our approach to advance our therapies. We each enjoy in the journey of advancing cutting edge programs, while responsibly teaching and learning together along the way.
Location: United States, South San Francisco
Member count: 201-500
Total raised: $90.5M

Investors 3

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
10.01.2014Series B$52M--
17.12.2013Series B$38.5M--

Mentions in press and media 13

09.04.2021John Robin...John Robin­son Biotech is a s...-Alex
01.03.2021Atara Biot...SOUTH SAN FRANCISCO, Calif.--(
04.12.2018Atara’s EB...What makes PTLD especially dif...--medcitynew...
29.06.2016The biotec...There was a time af­ter the 20...FinancingJohn
10.01.2014Atara Biot...Atara Biotherapeutics, Inc., a...funding
10.01.2014 Atara ...Thousand Oaks-based Atara Biot...--socaltech....
17.12.2013Atara Biot...Atara Biotherapeutics, Inc., a...funding
17.12.2013Atara Biot... BRISBANE, Calif. and THOUS...--domainvc.c...
17.12.2013 Atara ...Thousand Oaks-based biopharmac...--socaltech....
01.11.2012 Atara ...Thousand Oaks-based Amgen and ...--socaltech....
Show more